RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Nanfang Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorNanfang Hospital南方医科大学南方医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05825443, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. For patients with non-small cell lung cancer who have undergone surgical resection, the TNM stage after surgery is IIA-IIIA;

    Inclusion criterion 2

  3. The patient can recover within 3-8 weeks after the operation, and receive postoperative adjuvant treatment;

    Inclusion criterion 5

  4. The ECOG PS score is 0 or 1;

    Inclusion criterion 6

  5. Absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, hemoglobin ≥ 9g/dL;

    Inclusion criterion 9

    Total bilirubin ≤ 1.5 ULN; AST and ALT ≤ 2.5 ULN;

    Inclusion criterion 10

    Serum creatinine ≤ 1.25 ULN, or serum creatinine clearance ≥ 60ml/min;

    Inclusion criterion 11

  6. History of HIV infection, active period of HCV infection, active period of HBV infection (HBV-DNA>1000 copies/ml);

    Exclusion criterion 6

  7. Female patients must meet: menopause or have undergone surgical sterilization. Women with fertility must take effective contraceptive measures. Do not breastfeed.

    Inclusion criterion 12

    During pregnancy or lactation;

    Exclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05825443, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Sign the informed consent form before starting the study;
  • For patients with non-small cell lung cancer who have undergone surgical resection, the TNM stage after surgery is IIA-IIIA;
  • Patients cannot receive targeted adjuvant therapy;
  • 18-80 years old;
  • The patient can recover within 3-8 weeks after the operation, and receive postoperative adjuvant treatment;
  • The ECOG PS score is 0 or 1;
  • Have not received any chemotherapy for non-small cell lung cancer before enrollment;
  • Within 7 days before enrollment, the laboratory inspection must meet all the following requirements:
  • Absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, hemoglobin ≥ 9g/dL;
  • Total bilirubin ≤ 1.5 ULN; AST and ALT ≤ 2.5 ULN;
  • Serum creatinine ≤ 1.25 ULN, or serum creatinine clearance ≥ 60ml/min;
  • Female patients must meet: menopause or have undergone surgical sterilization. Women with fertility must take effective contraceptive measures. Do not breastfeed.
  • Male patients must agree to use appropriate contraceptive measures.

Exclusion Criteria:

  • Known or suspected to be allergic to the drug or any component of the drug related to the test;
  • Patients who can receive targeted treatment;
  • Other malignant tumors in five years before enrollment, excluding the cured cervical carcinoma in situ, the cured skin basal cell carcinoma, and other types of tumors that were cured only after surgical treatment;
  • Myocardial infarction, unstable angina pectoris and grade II congestive heart failure in six months before enrollment; New angina pectoris occurred within 3 months; Ventricular arrhythmia requiring medication;
  • Uncontrolled hypertension after treatment with antihypertensive drugs, i.e. systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg;
  • History of HIV infection, active period of HCV infection, active period of HBV infection (HBV-DNA>1000 copies/ml);
  • The researcher judged that there was a risk of bleeding;
  • Active severe clinical infection (≥ grade 3 CTCAE V5.0);
  • Epilepsy patients who need medication;
  • Allogeneic organ transplantation;
  • Patients who need kidney dialysis;
  • Thrombotic or embolic venous or arterial events occurred within six months before enrollment;
  • Serious uncured wounds, ulcers or fractures;
  • Interstitial pneumonia;
  • Any malabsorption disease;
  • Any disease that is unstable or may endanger the patient's safety;
  • Drug abuse, medical, psychological or social diseases;
  • Participate in other clinical studies within 3 months before enrollment;
  • During pregnancy or lactation;

Quoted from ClinicalTrials.gov, NCT05825443, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05825443, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05825443